Mereo BioPharma Group PLC ADR (MREO) - Total Assets
Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) holds total assets worth $34.71 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mereo BioPharma Group PLC ADR - Total Assets Trend (2015–2025)
This chart illustrates how Mereo BioPharma Group PLC ADR's total assets have evolved over time, based on quarterly financial data. Also see MREO market cap for the company's overall valuation and market capitalisation.
Mereo BioPharma Group PLC ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
Mereo BioPharma Group PLC ADR's total assets of $34.71 Million consist of 98.1% current assets and 2.0% non-current assets. Review MREO total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.3% |
| Accounts Receivable | $1.98 Million | 4.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $516.00K | 1.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Mereo BioPharma Group PLC ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MREO share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mereo BioPharma Group PLC ADR's current assets represent 98.1% of total assets in 2025, an increase from 75.8% in 2015.
- Cash Position: Cash and equivalents constituted 89.3% of total assets in 2025, up from 74.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 24.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 4.3% of total assets.
Mereo BioPharma Group PLC ADR Competitors by Total Assets
Key competitors of Mereo BioPharma Group PLC ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Mereo BioPharma Group PLC ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.88 | 8.13 | 7.92 |
| Quick Ratio | 5.88 | 8.13 | 7.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.72 Million | $53.86 Million | $116.94 Million |
Mereo BioPharma Group PLC ADR - Advanced Valuation Insights
This section examines the relationship between Mereo BioPharma Group PLC ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.35 |
| Latest Market Cap to Assets Ratio | 1.06 |
| Asset Growth Rate (YoY) | -39.9% |
| Total Assets | $45.92 Million |
| Market Capitalization | $48.79 Million USD |
Valuation Analysis
Above Book Valuation: The market values Mereo BioPharma Group PLC ADR's assets above their book value (1.06x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Mereo BioPharma Group PLC ADR's assets decreased by 39.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual total assets of Mereo BioPharma Group PLC ADR from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $45.92 Million | -39.89% |
| 2024-12-31 | $76.39 Million | +14.87% |
| 2023-12-31 | $66.50 Million | -14.10% |
| 2022-12-31 | $77.41 Million | -54.72% |
| 2021-12-31 | $170.96 Million | +98.60% |
| 2020-12-31 | $86.08 Million | -24.83% |
| 2019-12-31 | $114.52 Million | +70.22% |
| 2018-12-31 | $67.28 Million | -30.16% |
| 2017-12-31 | $96.34 Million | +11.03% |
| 2016-12-31 | $86.76 Million | -19.14% |
| 2015-12-31 | $107.30 Million | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more